Entrada Therapeutics, Inc. business relationships
Companies named in Entrada Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Entrada Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 5 / 100 Top 3% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Layers: Peptides
Named in Entrada Therapeutics, Inc.’s annual report 2
“Strategic Collaboration and License Agreement, dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated, as amended by Amendment No. 1 on October 26, 2023 (incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K filed by the Registrant on Mar...” SEC filing
“In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with dosing completion anticipated in mid-2026.” SEC filing
Companies whose annual reports name Entrada Therapeutics, Inc. 2
“• Entrada Therapeutics, Inc. In 2022, we established a collaboration with Entrada focused on enabling efficient” SEC filing
“VX-670, an endosomal escape vehicle technology with a CUG steric blocker oligonucleotide by Entrada Therapeutics, Inc. in collaboration with Vertex Pharmaceuticals Incorporated, or Vertex, being evaluated in a Phase 1/2 clinical trial in Canada, the United Kingdom, the European Union and Australia;...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.